Daniel Gerald Marquess, 562037 Touraine Ln, Princeton By The Sea, CA 94019

6479498, Nov 12, 2002

Nov 9, 2001

10/039699

Daniel Marquess - Half Moon Bay CA
Seok-Ki Choi - Palo Alto CA
David T. Beattie - Belmont CA
John H. Griffin - Atherton CA
Scott Armstrong - San Francisco CA
Timothy J. Church - San Mateo CA
Thomas E. Jenkins - La Honda CA
David C. Green - Pacifica CA

Theravance, Inc. - South San Francisco CA

C07D23942

514256, 514275, 544325, 544326, 544327, 544329

The compounds of this invention comprise 2-10 ligands covalently connected, each of the ligands being capable of binding to a ligand binding site in a Na channel, thereby modulating the biological activities thereof.

6646012, Nov 11, 2003

Jan 15, 2002

10/050696

Seok-Ki Choi - Pala Alto CA
Paul R. Fatheree - San Francisco CA
David C. Green - Pacifica CA
Daniel Marquess - Half Moon Bay CA

Theravance, Inc. - South San Francisco CA

C07C21103

514651, 564347

The invention provides sodium channel modulating compounds which are useful for treating diseases or conditions associated with sodium channel activity, such as neuropathic pain. The invention also provides pharmaceutical compositions comprising a compound of the present invention, as well as therapeutic methods comprising administering such a compound or salt to a mammal (e. g. a human).

6693202, Feb 17, 2004

Aug 25, 2000

09/645609

James Aggen - San Francisco CA
John H. Griffin - Atherton CA
Mathai Mammen - San Mateo CA
Daniel Marquess - Half Moon Bay CA
Edmund J. Moran - San Francisco CA
David Oare - Belmont CA

Theravance, Inc. - South San Francisco CA

C07D20700

548537, 435 71, 435 72, 436501, 436518, 514 79, 51425212, 514315, 514317, 514361, 514419, 514482, 514506, 514588, 540450, 544358, 546190, 546191, 546192, 546244, 548400, 548469, 548473, 548477, 548486, 548530, 548517, 548518, 548519, 548520, 548521, 562400

Disclosed are multibinding compounds which are muscarinic receptor antagonists. The multibinding compounds of this invention containing from 2 to 10 ligands covalently attached to one or more linkers. Each ligand is, independently of each other, a muscarinic receptor antagonist or an allosteric modulator provided that at least one of said ligand is a muscarinic receptor antagonist. The multibinding compounds of this invention are useful in the treatment and prevention of diseases such as chronic obstructive pulmonary disease, chronic bronchitis, irritable bowel syndrome, urinary incontinence, and the like.

6756400, Jun 29, 2004

Aug 30, 2001

09/943420

Jason P. Chinn - Petaluma CA
Seok-Ki Choi - Palo Alto CA
Paul R. Fatheree - San Francisco CA
Daniel Marquess - Half Moon Bay CA
S. Derek Turner - Pacifica CA

Theravance, Inc. - South San Francisco CA

C07D40312

514422, 548519

The invention provides sodium channel modulating compounds of formula I: wherein X, Y, Q, R , w, and R have any of the values defined in the specification, and salts thereof, which are useful for treating diseases or conditions associated with sodium channel activity, such as neuropathic pain. The invention also provides pharmaceutical compositions comprising a compound of formula (I) or a salt thereof, as well as therapeutic methods comprising administering such a compound or salt to a mammal (e. g. a human).

6872741, Mar 29, 2005

Sep 11, 2003

10/659931

Seok-Ki Choi - Palo Alto CA, US
Paul R. Fatheree - San Francisco CA, US
David C. Green - Pacifica CA, US
Daniel Marquess - Half Moon Bay CA, US

Theravance, Inc. - South San Francisco CA

A61K031/415
A61K031/4164
A61K031/5375
C07D233/54
C07D231/10

514396, 544139, 546184, 546248, 5462727, 5483401, 5483561, 5483751, 5483761, 5142358, 514397, 514399, 514406

The invention provides sodium channel modulating compounds which are useful for treating diseases or conditions associated with sodium channel activity, such as neuropathic pain. The invention also provides pharmaceutical compositions comprising a compound of the present invention, as well as therapeutic methods comprising administering such a compound or salt to a mammal (e. g. a human).

6878686, Apr 12, 2005

May 23, 2003

10/444847

Daniel Marquess - Half Moon Bay CA, US
Martin S. Linsell - San Francisco CA, US
S. Derek Turner - San Francisco CA, US
Sean G. Trapp - San Francisco CA, US
Daniel D. Long - San Francisco CA, US
Paul R. Fatheree - San Francisco CA, US

Theravance, Inc. - South San Francisco CA

A61K038/16

514 8

This invention provides cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.

6974797, Dec 13, 2005

Oct 11, 2002

10/269471

Paul R. Fatheree - San Francisco CA, US
Martin S. Linsell - San Francisco CA, US
Daniel D. Long - San Francisco CA, US
Daniel Marquess - Half Moon Bay CA, US
Edmund J. Moran - San Francisco CA, US
Matthew B. Nodwell - San Francisco CA, US
S. Derek Turner - Pacifica CA, US
James Aggen - Burlingame CA, US

Theravance, Inc. - South San Francisco CA

A61K038/00

514 8

This invention provides cross-linked glycopeptide—cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.

6995138, Feb 7, 2006

Oct 18, 2004

10/967578

Daniel Marquess - Half Moon Bay CA, US
Martin S. Linsell - San Francisco CA, US
S. Derek Turner - San Francisco CA, US
Sean G. Trapp - San Francisco CA, US
Daniel D. Long - San Francisco CA, US
Paul R. Fatheree - San Francisco CA, US

Theravance, Inc. - South San Francisco CA

A61K 38/16

514 8

This invention provides cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.